Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date

Michael G McCusker 1
Dennis Orkoulas-Razis 2
Ranee Mehra 1

1 University of Maryland Medical Center, Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; 2 Department of Internal Medicine, University of Maryland Medical Center, Baltimore, MD, USA

Abstract: Relapsed and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a heterogeneous disease previously associated with poor prognosis and limited treatment options until the advent and implementation of immune checkpoint inhibitors (ICIs). The fully humanized monoclonal antibody pembrolizumab alone, or in combination with chemotherapy, was shown to have significantly improved overall survival (OS) when compared to the standard of care (SOC) EXTREME regimen consisting of the monoclonal antibody cetuximab combined with a platinum and 5-fluorouracil. Pembrolizumab with or without chemotherapy will soon supplant the EXTREME regimen that has been in use for over a decade. Given the fast-approaching significant change in the treatment algorithm for R/M HNSCC and the novelty of ICIs in general, it is important to review the literature to date to understand how this rapidly growing treatment class has come about and explore potential areas of research for the plethora of questions that remain unanswered in selecting patients appropriate for treatment with ICIs in the R/M setting. In this review, we explore the landmark trials leading to the use of ICIs for R/M HNSCC with a particular focus on pembrolizumab, the most well-studied ICI in this setting. We also provide an overview of the rationale behind the use of ICIs in relation to the immune system and challenges surrounding tumor heterogeneity and PD-L1 expression status, human papilloma virus (HPV) and the efficacy of ICI, potential of radiation therapy for enhancement of ICI response, and complications of immune-related adverse events (irAEs).

Keywords: head and neck cancer, immunotherapy, pembrolizumab, checkpoint inhibitors

Introduction
Head and neck cancer is the sixth most common malignancy worldwide with approximately 600,000 new cases diagnosed each year.1 A heterogeneous group of tumors arising from squamous epithelium of the lips, oral cavity, oropharynx, and larynx accounts for 90–95% of head and neck cancers. Multimodal therapies with surgery, radiation, and/or platinum-based chemoradiation are the mainstay of treatment for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC), yet disease recurs frequently (60%).2 Patients with either locoregionally recurrent or metastatic (30%) disease are left with few treatment options and poor prognoses.3,4 For relapse and/or metastatic (R/M) HNSCC not amenable to curative-intent treatment, first-line palliative chemotherapy was the mainstay of treatment for decades despite poor overall survival (median OS 10 months) and high morbidity. The “EXTREME” regimen consisting of the monoclonal antibody cetuximab which targets the epidermal growth factor receptor (EGFR), combined with a platinum and 5-fluorouracil was a commonly utilized regimen for fit patients.5 After progression,
treatment was usually limited to single-agent therapies; methotrexate was most commonly used and demonstrated an overall response rate (ORR) of approximately 6% and a median OS of 6 months. Treatment options for R/M disease that progressed beyond single-agent chemotherapy were severely limited until the development and implementation of a new class of immunotherapy in 2016.

PD-1 inhibitors are approved for the treatment of patients with R/M HNSCC who progressed on or after platinum-based chemotherapy. Monoclonal antibodies against programmed death receptor-1 (PD-1), programmed death receptor ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have shown lasting responses in a number of cancers and were rapidly expanded to use in HNSCC. To date, several ICIs have been studied in HNSCC (Table 1) and two of the most well-studied ICIs for the treatment of HNSCC in the R/M setting are the PD-1 inhibitors pembrolizumab and nivolumab. These agents were granted accelerated approval by the United States Food and Drug Administration (FDA) based on early data from the nonrandomized KEYNOTE-012 trial for pembrolizumab and the CHECKMATE-141 trial for nivolumab. While there have been promising results with ICIs, optimal patient selection for treatment with ICIs has remained elusive. Fortunately, a number of investigations have addressed important patient- and disease-associated factors to guide clinicians in appropriate patient selection. This review examines available data on ICIs and, in particular, updated data with pembrolizumab for use in the treatment of HNSCC as it relates to PD-L1 expression, human papilloma virus (HPV) infection, radiation therapy, and immune-related adverse events (irAEs).

**Biology of Head and Neck Squamous Cell Carcinoma**

Genetic alterations and immune system disruption are the hallmark of cancer and HNSCC is a highly immunogenic cancer. Infection with high-risk HPV is a contributor to the pathogenesis of HNSCC and oropharyngeal cancer in particular in a large subset of HNSCC cancers, and the incidence of HPV-associated HNSCC continues to rise. HPV-associated HNSCC is found in approximately 40–80% of patients in the United States, as opposed to Europe where tobacco- and alcohol-associated HNSCC is more prevalent than HPV-related disease. Overall, HPV-associated HNSCC of oropharyngeal origin is seen in younger, predominantly white males of higher socioeconomic status (SES). Genotypes 16 and 18 are more commonly seen in the United States compared to Europe and Asia, but this is largely due to the fact that HNSCC is primarily non-HPV related in these regions. HPV genotype 16 (p16) accounts for over 90% of cases. HNSCC was down-trending in the 1980s, when alcohol and tobacco were the primary drivers of carcinogenesis. However, a rise in HPV infection has correlated with an increased incidence of HNSCC. This is reflected in a recent incidence analysis per 100,000 of HPV-positive (4.62, 95% CI=4.51–4.73) versus HPV-negative (1.82, 95% CI=1.75–1.89) HNSCC patients.

In HPV-associated disease, HPV promotes carcinogenesis by integrating into the DNA of the host leading to activation of oncoproteins E6 and E7, which in turn dysregulate tumor suppressors TP53 and Rb, respectively. TP53, one of the most important tumor suppressor genes encoding for a transcription factor with roles in DNA repair, cell cycle regulation, apoptosis, and genomic stability is mutated in approximately 80% of HPV-negative cases, as TP53 is degraded by HPV oncoprotein E6 in HPV-positive disease. The aforementioned process leads to immune response evasion through cytokine and chemokine expression and antigen presentation, IFNγ pathway down-regulation, and an immune-privileged state for the tumor. In contrast, HPV-negative HNSCC is associated with TP53 mutations and down-regulation of p16. Thus, p16 is a biomarker for HPV

### Table 1: Immunotherapies and PD-L1 Testing Methods

<table>
<thead>
<tr>
<th>Agent</th>
<th>Class</th>
<th>Target</th>
<th>PD-L1 Antibody</th>
<th>Antibody Host Species</th>
<th>Platform</th>
<th>PD-L1 Positivity Cut-Off</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pembrolizumab</td>
<td>IgG4</td>
<td>PD-1</td>
<td>22C3*</td>
<td>Mouse</td>
<td>Dako Autostainer Link 48</td>
<td>TC or IC &gt; 1%, &gt; 50%</td>
</tr>
<tr>
<td>Nivolumab</td>
<td>IgG4</td>
<td>PD-1</td>
<td>28–8*</td>
<td>Rabbit</td>
<td>Dako Autostainer Link 48</td>
<td>TC &gt; 1%, &gt; 5%, &gt;10%</td>
</tr>
<tr>
<td>Atezolizumab</td>
<td>IgG1</td>
<td>PD-L1</td>
<td>SP442</td>
<td>Rabbit</td>
<td>Ventana Benchmark Ultra</td>
<td>TC ≥ 5%; IC ≥5%</td>
</tr>
<tr>
<td>Durvalumab</td>
<td>IgG1</td>
<td>PD-L1</td>
<td>SP263</td>
<td>Rabbit</td>
<td>Ventana Benchmark Ultra</td>
<td>TC ≥ 25%</td>
</tr>
<tr>
<td>Avelumab</td>
<td>IgG1</td>
<td>PD-L1</td>
<td>73–10*</td>
<td>Rabbit</td>
<td>Dako Autostainer Link 48</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Notes:** *Dako North America; †Ventana Medical Systems Inc., Tucson, AZ.*

**Abbreviations:** TC, tumor cells; IC, immune cells.

---

OncoTargets and Therapy 2020:13
infection amongst oropharyngeal primary sites, with a cutoff point greater than 70% by immunohistochemistry (IHC) considered HPV-positive disease.\textsuperscript{18} TP53 mutations occur early in carcinogenesis and are associated with poor prognosis, therapy resistance, and increased recurrence rate in both HPV-positive and negative disease.\textsuperscript{19} The retinoblastoma (RB) tumor suppressor regulates cell cycle progression and also represents an early alteration in HNSCC tumorigenesis. In HPV-positive disease, viral protein E7 degrades RB and leads to E2F activation and uncontrolled proliferation.\textsuperscript{20,21} Further mutations have been discovered,\textsuperscript{22} beyond those previously identified that are involved in cell cycle regulation, apoptosis and DNA repair, and mutations in genes involved in the regulation of squamous cell differentiation (eg NOTCH1,\textsuperscript{23} IRF6,\textsuperscript{24} and TP63\textsuperscript{25}). Important differences in the specific alterations in PI3K mutations between HPV-associated and HPV-unassociated disease have also been noted and may provide inferences on clinical outcomes for treatment with PI3K/mTOR inhibitors.\textsuperscript{26,27} These known and yet-to-be-discovered genomic alterations as well as familial susceptibility (eg. Fanconi anemia\textsuperscript{28}) to HNSCC will continue to clarify and identify potential therapeutic targets.

### Clinical Trials with Immune Checkpoint Inhibitors

The Phase Ib KEYNOTE-012 trial was one of the first studies to evaluate ICI in a population of patients with R/M HNSCC. Patients who had previously failed treatment with curative intent were enrolled. Sixty-three percent of patients had received prior platinum and cetuximab therapy. Historically, the expected response rate (RR) of third-line treatment in this setting was in the single digits.\textsuperscript{29} The safety and efficacy of pembrolizumab in R/M HNSCC was evaluated across two cohorts. The initial cohort required PD-L1 expression of 1% by IHC. Patients (N=60) were treated at a dose of 10mg/kg every 2 weeks. An expansion cohort\textsuperscript{30} was treated at a fixed dose of 200 mg (N=132). In the initial report, the overall response rate (ORR) was 18% (95% CI=8-32). Median progression-free survival (PFS) was 2 months (95% CI=2-4). Drug-related adverse events of any grade were 63% (n=38), with 17% (n=10) grade 3 and zero grade 4 drug-related adverse events, respectively.\textsuperscript{7} These promising results lead to the accelerated approval of pembrolizumab for R/M HNSCC by the FDA on August 6, 2016,\textsuperscript{31} with future studies confirming the efficacy of pembrolizumab in the R/M setting.

In the pooled analysis (N=192) of the initial (n=60) and expansion (n=132) cohorts of KEYNOTE-012, Mehra et al confirmed the efficacy and safety of pembrolizumab for R/M HNSCC.\textsuperscript{32} In the combined cohort, significantly higher response rates were observed in patients with (21%) versus without (6%) PD-L1 expression using combined positive score (CPS, p=0.023)\textsuperscript{33} but not in patients with (18%) versus without (19%) PD-L1 expression by tumor proportion score (TPS, p=0.461). Similar differences were observed for both PFS and OS when PD-L1 expression was assessed using CPS or TPS as outlined in the pooled analysis supplemental tables. The analysis also showed a correlation between PD-L1 and PD-L2 expression (p<0.001) with a higher ORR seen in patients expressing both PD-L1 and PD-L2 (23%) versus those only expressing PD-L1 (10%). Still, patients without expression of either biomarker responded at a clinical response rate of 9% suggesting that PD-L1 and PD-L2 biomarkers do not fully predict response to pembrolizumab, highlighting the need for further studies addressing novel predictive molecular signatures. Clearly, subsets of patients are potentially curable as 4% of patients in the pooled analysis obtained a complete response (CR) with pembrolizumab.

Noting the importance of the tumor microenvironment (TME) in ICI efficacy, the Phase II single-arm KEYNOTE-055\textsuperscript{34} study of 171 patients with R/M HNSCC further evaluated the exploratory biomarker CPS on patient outcomes given the response to pembrolizumab observed in the KEYNOTE-012\textsuperscript{7} trial. Patients resistant to both platinum chemotherapy and cetuximab with progression or recurrence within 6 months of the last dose of therapy were treated with pembrolizumab 200 mg IV every 3 weeks until disease progression or intolerance. The overall response rate for all patients was 16% (95% CI=11-23) with adverse events of any grade reported in 64% of patients (n=109) and grade 3 or greater in 15% of patients (n=26). In a retrospective analysis, based on a CPS cut-off of ≥1%, ORR was 18% (95% CI=12-25) in CPS positive patients and 12% (95% CI=2-30) in CPS negative patients. With a higher cutoff of CPS ≥ 50%, ORR dichotomies were even larger, changing to 27% (95% CI=15-42) and 13% (95% CI=7-20) in CPS positive and negative patients, respectively. Similar to KEYNOTE-012,\textsuperscript{7} the KEYNOTE-055\textsuperscript{34} trial does not advocate for the use of CPS as a determinate of patient selection, as a percentage of CPS negative patients still benefited from pembrolizumab, but only notes that PD-L1 expression is associated with improved outcomes.
The role of pembrolizumab in the treatment of R/M HNSCC was further studied in the randomized, open-label, international, Phase III KEYNOTE-040 study.9 Expanding upon the results of the single-arm KEYNOTE-0127 and KEYNOTE-05544 trials, 495 patients were randomly assigned to receive pembrolizumab (n=247) or investigator’s choice (n=248) of methotrexate, docetaxel, or cetuximab. At the time of prespecified final analysis of death, the outcome measure was lower in patients treated with pembrolizumab (72%) than those treated with SOC (80%, HR=0.82, p=0.0316) though the HR did not meet the predefined boundary for efficacy. However, after confirming the survival status of 12 patients, pembrolizumab met the efficacy boundary for OS with a one-sided alpha of less than 0.0175. Median OS was 8.4 months with pembrolizumab and 6.9 months with SOC, respectively. The benefit of pembrolizumab versus SOC was greater in patients with PD-L1 expression in both the tumor and the TME. The KEYNOTE-0409 trial showed the benefits of pembrolizumab over single-agent chemotherapy, a common third-line option for patients with R/M HNSCC.

In a trial investigating the PD-1 inhibitor nivolumab in recurrent HNSCC, the CHECKMATE-1418 trial addressed the same question as to the KEYNOTE-0409 trial. The phase III trial randomized 361 patients to receive nivolumab (n=240) or standard therapy (n=121) of methotrexate, docetaxel, or cetuximab as in KEYNOTE-040. Similarly, the primary endpoint was OS with secondary endpoints being PFS and the rate of objective response. Median OS for nivolumab was 7.5 months versus 5.1 months with SOC and median PFS was 2.0 months versus 2.3 months, respectively. However, there was a late separation in the Kaplan–Meyer curve, with PFS at 6 months of 19.7% with nivolumab versus 9.9% with SOC, respectively. These figures mirror KEYNOTE-040, albeit with nivolumab demonstrating shorter OS and PFS.

The important question of whether PD-1 inhibitor treatment is superior to the EXTREME regimen in R/M HNSCC was addressed in the KEYNOTE-04815 trial. For over a decade, the EXTREME regimen5 has been the SOC first-line treatment for R/M HNSCC. The randomized, open-label, international, phase III trial compared pembrolizumab monotherapy (n=301) to the EXTREME regimen (n=300) or pembrolizumab plus chemotherapy (n=126, cisplatin or carboplatin plus 5-fluorouracil) to EXTREME (n=110). The study analyzed two lower boundaries for maximum CPS positivity of ≥20 and ≥1. At the final analysis, superior OS was seen in patients with PD-L1 CPS ≥ 20, CPS ≥ 1, and the total population for pembrolizumab plus chemotherapy versus EXTREME. When pembrolizumab monotherapy was compared to EXTREME, OS was superior for patients with CPS ≥ 20 and ≥ 1, but not the overall population. Treatment-related adverse events were similar to previous trials. These data support the use of either pembrolizumab plus platinum-based chemotherapy in patients with R/M HNSCC, or pembrolizumab monotherapy for use in patients PD-L1 positive tumors as a new first-line treatment for R/M HNSCC. Future studies should further define appropriate patient selection for ICI treatment as current hypotheses remain largely theoretical and preclinical, and evidence of biomarkers for predicting response to therapy is lacking. Still, PD-L1 expression is the most widely used and heavily studied biomarkers for response to ICI, but clearly does not fully predict response to ICI.

Predictors of Response to Immune Checkpoint Inhibitors

PD-L1 Expression

The human immune system is a tightly regulated, complex network of co-stimulatory and co-inhibitory signals that serve as “immune checkpoints” to prevent exaggerated immune response and autoimmunity. T cell activation requires antigen recognition through human leukocyte antigen (HLA) peptide presentation combined with a “second signal” for full activation that is balanced by co-inhibitory signals.6 Tumors may exploit this balance through overexpression of “self” antigens to evade immune activation and destruction, and promote tumor proliferation, angiogenesis, and metastasis.7 Several checkpoints for potential tumor escape have been described, such as CTLA-4, T cell immunoglobulin mucin domain-3 (TIM-3), lymphocyte-activation gene 3 (LAG-3), and PD-1/PD-L1.8–10 PD-1 (CD279) is a CD28 family transmembrane receptor expressed on the surface of activated T cells, B cells, natural killer (NK) cells, and monocytes, but is absent on naïve T cells.41 Binding of PD-1 to its major ligands PD-L1 and PD-L2 causes the release of inhibitory cytokines and a “checked” T cell response.42 Pembrolizumab is a fully humanized IgG4 monoclonal antibody against PD-1, which seeks to disrupt this interaction and restore balance to allow for immune system recognition, activation, and destruction of tumor cells.43 In HNSCC, PD-L1 overexpression is found in 50–60% of patients,44 making it an appealing target for immunotherapy in patients with R/M disease. In general, PD-L1 expressing tumors tend to show improved response.
to anti-PD-1/-anti-PD-L1 therapies in comparison to PD-L1 non-expressing tumors across an array of different tumor types. Based on this rationale, a series of clinical trials have been conducted to study pembrolizumab (Table 2) in addition to other ICIs (Table 3) for HNSCC.

PD-L1 expression is highly variable and its predictive value in HNSCC is partially influenced by three major factors: (1) Incongruent use of PD-L1 assays between laboratories, (2) varying levels of PD-L1 positivity cutoff, and (3) intra-tumoral heterogeneity. Studies evaluating PD-L1 expression employ different protocols, antibodies, scoring systems, and cutoffs for positivity. The landmark randomized, open-label, phase III CHECKMATE-141 trial randomized 361 patients with recurrent HNSCC to nivolumab versus SOC in a 2:1 ratio. PD-L1 expression was determined using a rabbit antihuman PD-L1 antibody by immunohistochemical (IHC) testing (Dako North America, clone 28–8, Epitomics) using cut-off levels of 1% or more, 5% or more, and 10% or more in a minimum of 100 tumor cells. In contrast, the phase III KEYNOTE-048 trial evaluated PD-L1 status using PD-L1 22C3 pharmDx assay (Agilent) and was scored using TPS of 50% or more and CPS of 20 or more. PD-L1 protein expression determined by TPS is defined as the percentage of viable tumor cells showing partial or complete membrane staining. A combined positive score represents the number of PD-L1 staining cells (tumor cells, lymphocytes, and macrophages) divided by the total number of viable tumor cells and is presented as a percentage. In the international, multi-institutional, phase II HAWK study of durvalumab for patients with R/M HNSCC, the VENTANA PD-L1 (SP263) Assay (Ventana Medical Systems, Inc., Tucson, AZ, USA) was used and PD-L1 tumor cells were scored PD-L1 high if expression was 25% or more; OS was 7.1 months (95% CI=4.9–9.9) in patients treated with durvalumab, a human immunoglobulin G1 kappa (IgG1 κ) monoclonal antibody that blocks the interaction of PD-L1 with PD-1. In general, comparisons across trials are not advised, but as more immunotherapy-based treatments and combination therapies are developed, a standardized approach is needed to ensure proper determination of PD-L1 as a predictive marker of response to ICI.

Intra-tumoral heterogeneity challenges pathologists across a number of tumor types, and HNSCC is no exception. In a study of intra-tumoral PD-L1 expression variability, Rasmussen et al performed 6 random core biopsies on 33 surgical specimens from 28 patients with HNSCC and compared PD-L1 concordance percentages (all positive or all negative). With a cut-off of 1% or more PD-L1 expression, TPS and CPS concordance was 36% and 52%, respectively. The concordance increased with a cut-off value of 50% or more for TPS (70%) and CPS (54%), respectively. Further, the negative predictive value (NPV) of a single negative biopsy with CPS using a cut-off value of 1% or more was 0% (ie none of the 6 biopsies from 33 samples had no PD-L1 expression). However, using the 50% cut-off value, NPV was 79.9% with TPS and 62.8% with CPS. In a population of patients with R/M HNSCC where single biopsies for disease recurrence confirmation are common, the predictive value of PD-L1 expression using a single core biopsy gives caution to clinicians in determining if ICI is the appropriate treatment, and supports the necessity of tissue preservation at the time of surgery where PD-L1 expression may be assessed using multiple samples from both primary and metastatic disease sites.

HPV Infection
HPV-positive HNSCC is associated with a better overall prognosis in the setting of both locoregional and metastatic disease, in spite of a more aggressive disease course. In the ICON-S study, 5-year OS in HPV-positive HNSCC in stages I, II, III, IVa, and IVb were 88%, 82%, 84%, 81%, and 60%, respectively, versus 76%, 68%, 53%, 45%, and 34% in HPV-negative HNSCC. HPV-positive tumors were found earlier (T1, T2) with more frequent nodal involvement. Still, HPV-positive tumors progress less frequently, and upon progression, a better OS is seen with a median OS of approximately 2.6 years and 0.8 years in HPV positive and negative tumors, respectively. An analysis of HPV status in R/M HNSCC with SOC treatment showed a median OS in HPV-positive patients of 12.9 months versus 6.7 months in HPV-negative patients. Similar results were found in p16 positive (11.9 months) versus p16 negative (6.7 months) patients. A retrospective analysis of the EXTREME trial yielded comparable results.

The impaired ability of the immune system to control both HPV-positive and negative tumors is evidenced by high levels of cytotoxic CD8 positive and activated NK cell activity in HNSCC, yet diminished tumor control. The tumor microenvironment has been shown to suffer from defective tumor-infiltrating lymphocytes, impaired ability of T cells to recognize cancer cells, and activation of MAPK, STAT3, and B-catenin/wnt signaling pathways. Despite the heavy immune presence in the tumor microenvironment, tumors
### Table 2: Clinical Trials of Pembrolizumab in R/M HNSCC

<table>
<thead>
<tr>
<th>Trial</th>
<th>Phase</th>
<th>N</th>
<th>n</th>
<th>Treatment</th>
<th>PD-L1 Limit</th>
<th>ORR % (95% CI)</th>
<th>Median OS (Months, 95% CI)</th>
<th>Total</th>
<th>PD-L1 +</th>
<th>PD-L1 -</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total</td>
<td>PD-L1+</td>
<td>PD-L1-</td>
</tr>
<tr>
<td>KEYNOTE-012 initial</td>
<td>I</td>
<td>60</td>
<td>-</td>
<td>Pembrolizumab CPS ≥1%</td>
<td>18 (8–32)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>KEYNOTE-012 expansion</td>
<td>I</td>
<td>132</td>
<td>-</td>
<td>Pembrolizumab TC ≥1%</td>
<td>18 (12–26)</td>
<td>19 (12–29)</td>
<td>16 (7–31)</td>
<td>8 (6–10)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CPS ≥1%</td>
<td>22 (14–31)</td>
<td>4 (0.1–20)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KEYNOTE-012 pooled</td>
<td>I</td>
<td>192</td>
<td>-</td>
<td>Pembrolizumab TC ≥1%</td>
<td>18 (13–24)</td>
<td>18 (12–26)</td>
<td>19 (10–30)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CPS ≥1%</td>
<td>21 (15–28)</td>
<td>6 (1–19)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KEYNOTE-055</td>
<td>II</td>
<td>171</td>
<td>-</td>
<td>Pembrolizumab CPS ≥1%</td>
<td>16</td>
<td>18 (12–25)</td>
<td>12 (2–30)</td>
<td>8 (6–11)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CPS ≥50%</td>
<td>27 (15–42)</td>
<td>13 (7–20)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KEYNOTE-040</td>
<td>III</td>
<td>495</td>
<td>247</td>
<td>Pembrolizumab CPS ≥1</td>
<td>14.6 (10.4–19.6)</td>
<td>17.3 (12.3–23.4)</td>
<td>4.0 (0.5–13.7)</td>
<td>8.4 (6.4–9.4)</td>
<td>8.7 (6.9–11.4)</td>
<td>6.3 (3.9–8.9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TC ≥50%</td>
<td>26.6 (16.3–39.1)</td>
<td>10.4 (6.4–15.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>248 SOC*</td>
<td></td>
<td></td>
<td></td>
<td>CPS ≥1</td>
<td>10.1 (6.6–14.5)</td>
<td>9.9 (6.1–15.1)</td>
<td>11.1 (4.2–22.6)</td>
<td>6.9 (5.9–8.0)</td>
<td>7.1 (5.7–8.3)</td>
<td>7.0 (5.1–9.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TC ≥50%</td>
<td>9.2 (3.5–19.0)</td>
<td>10.6 (6.5–16.0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KEYNOTE-048</td>
<td>III</td>
<td>882</td>
<td>126</td>
<td>Pembrolizumab CPS ≥1</td>
<td>36</td>
<td>36</td>
<td>13.0 (10.9–14.7)</td>
<td>13.6 (10.7–15.5)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CPS ≥20</td>
<td>43</td>
<td>-</td>
<td>14.7 (10.3–19.3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EXTREME</td>
<td>CPS ≥1</td>
<td>36</td>
<td>36</td>
<td>10.7 (9.3–11.7)</td>
<td>10.4 (9.1–11.7)</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CPS ≥20</td>
<td>38</td>
<td>-</td>
<td>11.0 (9.2–13.0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EXTREME</td>
<td>CPS ≥1</td>
<td>17</td>
<td>19</td>
<td>11.5 (10.3–13.4)</td>
<td>12.3 (10.8–14.3)</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CPS ≥20</td>
<td>23</td>
<td>-</td>
<td>14.8 (11.5–20.6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EXTREME</td>
<td>CPS ≥1</td>
<td>36</td>
<td>35</td>
<td>10.7 (9.3–11.7)</td>
<td>10.3 (9.0–11.5)</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CPS ≥20</td>
<td>36</td>
<td>-</td>
<td>10.7 (8.8–12.8)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** *Investigator’s choice of methotrexate 40 mg/m² IV qwk, docetaxel 75 mg/m² IV q3wk, or cetuximab 250 mg/m² qwk IV following a loading dose of 400 mg/m².

**Abbreviations:** CPS, combined positive score; TC, tumor cells; SOC, standard of care; All results determined by central review.
Table 3  Clinical Trials Evaluating Nivolumab, Durvalumab, and Atezolizumab in R/M HNSCC

<table>
<thead>
<tr>
<th>Trial</th>
<th>Phase</th>
<th>n</th>
<th>Treatment</th>
<th>PD-L1 Limit</th>
<th>ORR % (95% CI)</th>
<th>Median OS (Months, 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHECKMATE-141</td>
<td>III</td>
<td>361</td>
<td>Nivolumab</td>
<td>≥ 1%</td>
<td>13.3 (9.3–18.3)</td>
<td>7.5 (5.5–9.1)</td>
</tr>
<tr>
<td>MEDI4736-1108</td>
<td>I/II</td>
<td>62</td>
<td>Durvalumab</td>
<td>&gt;25%</td>
<td>16.2 (9.9–24.4)</td>
<td>5.1 (4.0–6.0)</td>
</tr>
<tr>
<td>CONDOOR</td>
<td>II</td>
<td>111</td>
<td>Durvalumab</td>
<td>≤ 25%</td>
<td>9.2 (3.4–19.0)</td>
<td>2.6 (0.1–13.5)</td>
</tr>
<tr>
<td>MED4736-11086</td>
<td>II</td>
<td>111</td>
<td>Durvalumab</td>
<td>&gt;25%</td>
<td>7.8 (3.78–13.79)</td>
<td>2.6 (0.1–13.5)</td>
</tr>
<tr>
<td>EAGLE</td>
<td>I</td>
<td>32</td>
<td>Atezolizumab</td>
<td>&gt;5%</td>
<td>22 (9–40)</td>
<td>14 (0.5–51.5)</td>
</tr>
</tbody>
</table>

Notes: *Investigator's choice of single-agent methotrexate, docetaxel, or cetuximab.  †Investigator's choice of cetuximab, taxane, methotrexate, or fluoropyrimidine-based regimen.  ‡Atezolizumab administered every 3 weeks for at least 15 mg/kg, 20 mg/kg, or 200 mg fixed dose. The first 10 patients were non-selectively enrolled. Subsequent enrollment was based on PD-L1 status of ≥50%. TC, tumor cells; SOC, standard of care.

Abbreviations: TC, tumor cells; SOC, standard of care.
are able to escape control, leading to an important hypothesis of immune system “reprogramming” and exploitation of neoantigens on cancer cells as a result of genomic alterations. Entertainment of this hypothesis contributed to the development of ICIs that will soon become the first line for the treatment of R/M HNSCC and studies continue to clarify important biomarkers and genomic alterations that have predictive and prognostic value for response to ICI treatment.

Throughout the KEYNOTE trials, subset analyses were performed on the effect of HPV (p16) positivity and response to pembrolizumab. The phase Ib KEYNOTE-012 trial showed greater ORR and PFS in HPV-positive (25%, 4 months) versus HPV-negative (19%, 2 months) tumors, respectively. The KEYNOTE-012 expansion cohort found similar differences in ORR in HPV-positive (32%) and HPV-negative (14%) tumors and 6 months PFS in HPV-positive (37%) and HPV-negative (20%) tumors. In the pooled data analysis of KEYNOTE-012, ORR was 24% and 16% in HPV-positive and HPV-negative tumors, respectively, with 18% demonstrating complete or partial response regardless of HPV status. Similar data were demonstrated in the phase II KEYNOTE-055 trial. However, PFS was similar among the two groups (2.1 months, 95% CI=2.1–2.1) with a median 6-month OS of all patients being 59% (72% in HPV-positive versus 55% in HPV-negative). KEYNOTE-048, which compared pembrolizumab with or without chemotherapy to the EXTREME regimen, showed clinical benefit from pembrolizumab regardless of HPV status. Thus, although HPV status is associated with a better prognosis as demonstrated throughout the KEYNOTE trials, it should be considered independent of PD-L1 status, as PD-L1 expression is observed in HPV-negative HNSCC as well. This is also reflected in CHECKMATE-141 where p16 positive patients, regardless of PD-L1 status had improved OS with nivolumab (9.1 months), compared to SOC (4.1 months). In turn, OS in PD-L1 positive patients was identical in the nivolumab group regardless of p16 status (8.8 months), underscoring that HPV status is a favorable independent prognostic factor, irrespective of treatment.

Tumor Mutational Burden

The genetic makeup and mutational burden of HNSCC has been extensively studied using microarray subgroup analyses based on mutational profile and predictive implications for response to immunotherapy are being defined. It is thought that tumors harboring more mutations may, in fact, lead to increased neoantigens and a more immunogenic response when treated with ICI. HPV-negative tumors (i.e., HNSCC likely secondary to risk factors such as tobacco and alcohol) generally have a higher TMB than HPV-positive tumors. In general, HNSCC tumors have high tumor mutational burden (TMB) when measured by a number of mutations per megabase (N mut/MB), as shown in a study using compressive genomic profiling of 1,184 HNSCC samples exhibiting a median of 5 mut/MB, regardless of HPV status and correlational studies of TMB and responsiveness to immunotherapy is an active area of research. In a pooled analysis evaluating the relationship between TMB and ORR for anti-PD-1 or anti-PD-L1 immunotherapies across multiple cancer types, Yarchoan et al observed a significant correlation between TMB and ORR with a correlation coefficient of 0.74 (p<0.001). The analysis included 19 studies using nivolumab and 20 studies using pembrolizumab in HNSCC. Using data from four KEYNOTE clinical trials from more than 300 patient samples of 22 different tumor types, Cristescu et al assessed the individual and joint clinical utility of the predictive biomarkers of TMB and T cell-inflamed gene expression profile (GEP) on the best overall response (BOR) to ICI. Patients were grouped according to TMB high (≥ Youden Index cut points) versus TMB low (< Youden Index cut points) and GEP (high versus low). TMB and GEP were modestly correlated, and each was independently predictive of response to ICI across the KEYNOTE trials. In HNSCC BOR was greatest in TMB high/PD-L1 positive (30%, 95% CI=17.3–44.9) and lowest for TMB low/PD-L1 negative (9%, 95% CI=0.2–41.3), but not statistically significant. Similarly, BOR was greatest for TMB high/GEP high tumors (37%, 95% CI=21.8–54.0) and lowest for TMB low/GEP low tumors (0%, 95% CI=0.0–21.8), but not statistically significant. In an analysis of biomarkers predictive of BOR to ICI in HNSCC, Seiwert et al evaluated a combined cohort of patients from KEYNOTE-012 (n=261) and KEYNOTE-055 (n=154). BOR was significantly correlated with TMB by whole-exome sequencing (WES), PD-L1 CPS, and GEP regardless of HPV status (p<0.01). Responses were higher in patients with both high TMB and PD-L1 CPS or GEP than in patients with low TMB and high PD-L1 CPS or GEP. As seen, TMB, GEP, and PD-L1 expression are predictive of response to ICI. However, key factors remain unaddressed before TMB is to be fully incorporated into treatment algorithms, such as the interplay between HPV and TMB, and the role of chemo- and/or immune-radiotherapy in the induction of neoantigens and T cell activation.
Pembrolizumab and Radiation Therapy

Radiation therapy is a mainstay of treatment for HNSCC and the effects of radiation on the immune system and responses to ICI are under active investigation with over 30 clinical trials in process for ICIs (e.g. NCT 03539198, 03383094, 03085719, 03844763, 03313804, 03283605, and 03258554). Radiotherapy can lead to both direct toxicity and immunomodulatory responses, leading to tumor cell death via T cell activation. Irradiated, apoptotic tumor cells release antigens that prime and activate cytotoxic T cells, leading to an abscopal effect of primed T cells recognizing non-irradiated tumor tissue. Preclinical studies evaluating radiotherapy with PD-L1 blockade have shown promising results, with the leading hypothesis that immunotherapy disrupts tumor evasion of T cell-mediated death induced by radiotherapy. A retrospective analysis of KEYNOTE-01 in patients with NSCLC treated with pembrolizumab and radiotherapy showed significantly longer PFS (HR=0.56, 95% CI=0.34–0.9, p=0.019) and OS (HR=0.58, 95% CI=0.36–0.94, p=0.026). Improved outcomes have also been shown with metastatic lung cancer with brain metastases, whereby patients underwent stereotactic irradiation. Translation of the effects of radiation therapy on response to ICI and vice versa to HNSCC patients is not yet fully understood. For example, recent research has shown that resistance to radiotherapy plus PD-L1 blockade may arise via the TIM-3 pathway and T reg activation.

In HNSCC, the ability of pembrolizumab to interfere with the PD-1/PD-L1 interaction and allow for T cell-mediated death of tumor cells primed by radiotherapy is promising for the future of HNSCC management. Early outcomes of ongoing Phase I and II trials (GORTEC 2015–01, RTOG 3504, NCT02641093) have been encouraging, but some trials have demonstrated increased adverse effects, mostly Grade 1 and 2. There are currently multiple ongoing clinical trials addressing the relationship between ICI and radiotherapy and the move to ICI-based treatment to the front-line setting is under investigation. The JAVELIN Head and Neck 100 (NCT02952586) global, multicenter, randomized, double-blind, phase III trial is currently evaluating the use of the fully human IgG1 anti-PD-L1 antibody avelumab plus cisplatin-based CRT versus placebo plus CRT as first-line treatment for patients with LA-HNSCC. A similar trial using pembrolizumab (NCT03040999), is the Phase III, randomized placebo-controlled, double-blind KEYNOTE-412 trial evaluating the efficacy and safety of pembrolizumab plus CRT in comparison to placebo plus CRT in the front-line setting for LA-HNSCC not treated by surgery. The open-label, phase III KEYNOTE-689 trial (NCT03765918) is evaluating the efficacy and safety of both neoadjuvant and adjuvant pembrolizumab in resectable LA-HNSCC.

Immune-Related Adverse Events with Pembrolizumab in Head and Neck Squamous Cell Carcinoma

A developing understanding of irAEs as a consequence of ICI is still being defined, and best prevention and treatment strategies remain unclear. The cause of irAEs is thought to be related to the aberrant action of activated T cells. Several possible mechanisms behind irAEs include: 1) Exacerbation of subclinical inflammation by ICI, 2) cross-reactivity of shared antigens between organs at risk and tumors, and 3) the negative impact of ICI on the gut microbiome. Early fears for clinicians using immunosuppression for treatment of irAEs were grounded in the fact irAEs were correlated with improvement in PFS, OS, and ORR, a phenomenon that was more notable in anti-PD-1/PD-L1 than anti-CTLA4 agents. Clinicians feared that dampening such a response would lead to inferior outcomes and prohibit the use of ICI in the future. However, as demonstrated in the KEYNOTE studies, irAEs are common, but are rarely severe enough to result in permanent discontinuation of ICI treatment.

In the KEYNOTE trials, no new adverse events using ICI were uncovered using pembrolizumab for HNSCC. At the final analysis of the phase III KEYNOTE-048 trial, adverse events of grades 3–5 that occurred in ≥5 participants occurred in pembrolizumab alone (55%), pembrolizumab plus chemotherapy (85%), and cetuximab with chemotherapy (83%) that are in line with prior studies using pembrolizumab and alternative PD-1 and PD-L1 ICIs. Not surprisingly, the addition of chemotherapy was associated with an increased incidence of adverse events. A list of prespecified “adverse events of interest” was analyzed at final analysis and includes factors that today might be referred to as irAEs, such as hypothyroidism, pneumonitis, and severe skin reactions. Here, what can be thought of as irAEs of grades 3–5 occurred in pembrolizumab alone (7%), pembrolizumab plus chemotherapy (5%), and cetuximab plus chemotherapy (10%). Hypothyroidism of any grade, the most common irAE, was more common in...
pembrolizumab alone (18%) and pembrolizumab plus chemotherapy (16%) than cetuximab plus chemotherapy (6%). However, there were no instances of grades 3–5 hypothyroidism in any of the participants. Expectedly, chemotherapy containing regimens were associated with higher instances of blood and lymphatic system disorders of grade 3–5 with anemia, in particular, occurring in pembrolizumab (5%), pembrolizumab plus chemotherapy (25%), and cetuximab plus chemotherapy (17%).

The risk of adverse events with higher intensity treatment regimens for R/M HNSCC has limited options for clinicians to treat patients with marginal performance status and heavily pretreated disease, but there is now a powerful single-agent option for patients who may not be candidates for combination chemoimmunotherapy. In contrast to the landmark phase III EXTREME trial, 5 single agent immunotherapy was compared to chemoimmunotherapy in the KEYNOTE-048 trial. Outcomes were better, and the incidence of adverse events was lower with single-agent pembrolizumab than chemoimmunotherapy. 35 Further, when comparing the chemoimmunotherapy groups, the pembrolizumab-containing group also outperformed the EXTREME regimen in terms of outcomes and adverse events, leaving clinicians with two options for treatment of R/M HNSCC: Less intensive single-agent immunotherapy with pembrolizumab and more intensive chemoimmunotherapy with pembrolizumab, cisplatin or carboplatin, and 5-fluorouracil. However, defining patient populations to benefit from ICI alone or chemoimmunotherapy will require further trials to identify predictive factors based on patient and tumor characteristics.

Conclusions

Immune checkpoint inhibitors have changed the landscape for the treatment of aggressive R/M HNSCC. Pembrolizumab with chemotherapy and pembrolizumab alone will soon become SOC in this setting. Still, there are many questions left unanswered in selecting patients and tumors that may respond favorably to ICIs. As more powerful and effective ICIs become available, further studies are needed on important topics, such as standardization for determination of PD-L1 expression between laboratories, clarification on ICI and its relation to timing and dosing with CRT, the role of combination CRT and ICI versus radiation therapy alone with ICI in the front-line setting, and the roles of molecular biomarkers such as PD-L2, TMB, and genomic signatures on responses to ICI. Nevertheless, excitement abounds with the use of a new class of ICI with generally mild and well-tolerated side effects for a group of patients previously left with few and poor options for treatment of R/M HNSCC.

Disclosure

Dr Ranee Mehra reports research funds from Merck, Astra Zeneca, personal fees from Bayer, outside the submitted work. The authors report no other conflicts of interest in this work.

References


McCusker et al

DovePress

OncoTargets and Therapy 2020:13


61. McCusker et al. doi:10.1002/1463-1320.eitp316.000122


